 

Active ingredient: Acyclovir 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-treatment, two-period crossover in-vivo 
Strength: 800 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-treatment, two-period crossover in-vivo 
Strength: 800 mg 

Subjects: Normal healthy males and females, general population 

Additional comments: 




______________________________________________________________________________ 

 

Analytes to measure: Acyclovir in plasma. 

 

Bioequivalence based on (90% CI): Acyclovir 

 

Waiver request of in-vivo testing: 400 mg based on (i) acceptable bioequivalence studies on 
the 800 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) 
acceptable in vitro dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please conduct comparative dissolution testing on 12 dosage units of all strengths of the test and 
reference products using the following USP method. 


